Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Botox with HoLEP for BPH and OAB
NCT05393921Phase 4Withdrawn
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of botulinum toxin type A in overactive bladder (OAB) (2 arms), sponsored by University Hospitals Cleveland Medical Center. Primary endpoints: International Prostate Symptom Score at 6 months, Overactive Bladder Symptom Score at 6 months and 2 more. Planned start Jun 2026; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05393921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393921.